Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Vir Biotechnology, Inc. is a clinical-stage biotechnology company focused on the discovery and development of therapies for serious infectious diseases with significant unmet medical need. The company operates within the biopharmaceutical and biotechnology industries, applying immunology, antibody engineering, and T-cell–based technologies to target viral pathogens. Vir’s activities are primarily research- and development-driven, with revenue historically derived from strategic collaborations rather than product sales.
The company’s core programs address chronic hepatitis B, influenza, and other viral diseases, and it is widely known for its role in developing sotrovimab, a monoclonal antibody for COVID‑19, in partnership with GlaxoSmithKline (GSK). Vir was founded in 2016 and built its platform through a combination of internal research and partnerships with academic institutions and large pharmaceutical companies, positioning itself as a science-driven organization focused on immune-mediated viral control rather than traditional antiviral approaches.
Business Operations
Vir operates as a single-reportable segment biotechnology company, with business activities centered on research, clinical development, and strategic collaborations. The company generates revenue primarily through collaboration agreements, licensing arrangements, and research funding, rather than commercial product sales. Key programs include antibody-based therapies and T‑cell–focused approaches targeting viral persistence and immune evasion.
Operations are conducted mainly in the United States, with R&D facilities and corporate functions supporting discovery, preclinical research, and clinical trial management. Vir controls proprietary technology platforms related to monoclonal antibodies, T-cell–based immunity, and innate immune modulation. Major partnerships include its long-standing collaboration with GlaxoSmithKline (GSK) for infectious disease antibodies and its regional hepatitis B collaboration with Brii Biosciences for Greater China, which provides development and commercialization support in that market.
Strategic Position & Investments
Vir’s strategy centers on building a pipeline of differentiated immunologic therapies that can potentially deliver functional cures or durable protection against viral diseases. A key strategic focus is chronic hepatitis B, where Vir is advancing multiple clinical-stage assets designed to reduce viral load and restore immune control through combination therapy approaches.
The company has made targeted investments through partnerships rather than large-scale acquisitions, leveraging external expertise to expand global reach while conserving capital. Notable strategic assets include its hepatitis B portfolio developed with Brii Biosciences and antibody programs co-developed with GlaxoSmithKline (GSK). Vir continues to invest in emerging immunology technologies, including T-cell–based viral targeting, as part of its long-term innovation strategy.
Geographic Footprint
Vir Biotechnology is headquartered in San Francisco, California, and its primary operations are based in the United States. The company’s clinical development activities extend internationally through global clinical trials and regulatory interactions, particularly in regions with high prevalence of infectious diseases such as Asia.
Through strategic collaborations, Vir has an operational and commercial footprint beyond North America, most notably in Greater China via its partnership with Brii Biosciences, and globally through GSK’s development and commercialization infrastructure. While Vir does not maintain extensive foreign manufacturing or sales operations, its international influence is driven by these partnerships and multinational clinical programs.
Leadership & Governance
Vir was founded in 2016 by Robert T. Baffi and co-founders with backgrounds in biotechnology investing, pharmaceuticals, and global health. The leadership team emphasizes a science-first culture, long-term value creation, and the application of cutting-edge immunology to infectious disease challenges.
Key executives include:
- Marianne De Backer – Chief Executive Officer
- Robert T. Baffi – Co-Founder and President
- Mark Eisner – Chief Financial Officer
- Phil Pang – Chief Medical Officer
- Anand Mehra – Chief Technical Officer
The company is governed by a board with experience in biotechnology, pharmaceuticals, and capital markets, and management has articulated a strategic vision focused on disciplined R&D investment, selective partnerships, and advancing programs with the potential for transformational clinical impact.